DocWire News Editors

DocwireNews

A new consensus document of recommendations for the prevention of the &ldquo;nocebo&rdquo; effect in biosimilar-treated patients with irritable bowel disease (IBD) noted that the issue was under-recognized and may negatively impact cost savings.The authors of the NOCE-BIO Consensus Group, publishing the document in Alimentary and Therapeutics, convened a group consisting of 19 members from across Europe. In their introduction, the researchers took care to explain what the nocebo effect was, defining it as &ldquo;a negative effect of a pharmacological or nonpharmacological medical treatment that is induced by patients&rsquo; expectations, and that is unrelated to the physiological action of the treatment.&rdquo; Whether or not the nocebo effect leads to unnecessary cessation of treatment, they said, comes mainly indirectly from open-label studies rather than double-blind studies. To this end, the writing group set out to review the literature and develop recommendations for prevention and management of the nocebo effect in IBD &nbsp;patients treated with biosimilars. They agreed upon the recommendations, with varying levels of evidence, via a voting process detailed in the manuscript. A statement was considered &ldquo;accepted&rdquo; if more than 75% of participants voted to agree (4) or strongly agree (5) on a scale of 1 to 5.The authors focused specifically on information about prevention and management of the nocebo effect was undertaken. While conducting their search across PubMed/MEDLINE, EMBASE and the Cochrane Central Database, they noted that randomized controlled trials looking specifically at these things &ldquo;were lacking,&rdquo; noting that only one interventional study looking at the nocebo response rate in biosimilar-treated IBD patients could be located. A majority of the indirect evidence they found &ldquo;was extrapolated from studies conducted in patients with rheumatic diseases.&rdquo; No data on etiology and risk factors of the nocebo effect for this population could be located, although one systematic review was able to summarize contributing factors.According to their results, the nocebo effect occurred in 12.8% of patients in one of the studies converting patients with different immune-mediated inflammatory diseases from infliximab originators to a biosimilar (an open-label outcomes study of 260 patients, 64 of whom had IBD), and then evaluated the nocebo effect for other indications. In the studies involving patients with rheumatological conditions, they observed similar rates between them and the biosimilar-treated patients with IBD. They identified five predictors of the nocebo effect: learning by social observations; perceived dose; verbal suggestions for arousal and symptoms; type of clinical condition, and baselines symptom expectations.&ldquo;The nocebo effect is under&#8208;recognized in the era of biosimilars, although it may negatively impact on the cost&#8208;savings of biosimilars,&rdquo; they concluded. &ldquo;Future research should focus on the magnitude, the risk factors, the impact, and the management of the nocebo effect in biosimilars&#8208;treated IBD patients.&rdquo;Read more at <a href="https://onlinelibrary.wiley.com/doi/full/10.1111/apt.15223">Alimentary Pharmacology and Therapeutics&nbsp;</a>

Jordana Jampel

Positive Preliminary Results From Phase 1 Trial of Dopaminergic Neuron Graft for Parkinson’s Disease

Dementia

Bradley Warady, MD

Joel M. Topf, MD, FACP

2025 Hume Award Winner Is Dedicated to Children’s Care

NKF Spring Clinical Meetings 2025

Distant Brain Metastases in Cutaneous Melanoma May Be Mitigated With Multiple Pathway Inhibitors

Melanoma

Latest News

The Nocebo Effect in Biosimilar-treated Patients with Irritable Bowel Syndrome

Gastroenterology

A new consensus document of recommendations for the prevention of the “nocebo” effect in biosimilar-treated patients with irritable bowel disease (IBD) noted that the ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe